[A24-79] Dupilumab (COPD) – Benefit assessment according to §35a Social Code Book V
Last updated 06.03.2025
Project no.:
A24-79
Commission:
Commission awarded on 31.07.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Add-on maintenance treatment of adult patients with uncontrolled COPD characterized by raised blood eosinophils on a combination of an inhaled corticosteroid, a long-acting beta-2 agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if an inhaled corticosteroid is not appropriate
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the Dossier assessment replaces version 1.0 published on 2024-11-04.
https://doi.org/10.60584/A24-79_en
Federal Joint Committee (G-BA)
2025-02-06 A G-BA decision was published.